Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

Leerink Partners analyst maintained a Buy rating on Scholar Rock Holding today and set a price target of $65.00. In addition to Leerink Partners, S...

Leerink Partners Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

Scholar Rock Holding ( ($SRRK) ) has provided an update. On September 14, 2026, Scholar Rock Holding announced via an investor webcast that the U.S...

Scholar Rock Highlights FDA Approval and Safety Commitments

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK), Veracyte (VCYT) and Con...

Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Veracyte (VCYT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Scholar Rock Holding (SRRK) and Whitehawk Therapeuti...

Analysts’ Top Healthcare Picks: Scholar Rock Holding (SRRK), Whitehawk Therapeutics (WHWK)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Scholar Rock Holding, with a price target of $64.00. Accordi...

Wedbush Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Scholar Rock Holding (SRRK), Axsome Therapeutics (...

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK), Axsome Therapeutics (AXSM) and Ionis Pharmaceuticals (IONS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Summit Therapeutics (SMMT), Scholar Rock Holding (SR...

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Faeth Therapeutics (FTH), 4D Molecular Therapeutics ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$48.61	-2.49%	2.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRRK	$48.61	-2.5%	2.01M
3
4
5
6

SRRK

Get Scholar Rock Holding Corporation Data in Excel

Get Scholar Rock Holding Corporation Data in Excel